Image: The Eversense implantable CGM sensor (Photo courtesy of Senseonics).
A novel continuous glucose monitoring (CGM) system measures interstitial fluid glucose levels in adults with diabetes for up to 180 days.
The Senseonics (Germantown, MD, USA) Eversense XL CGM system is designed to continuously monitor glucose levels below the skin surface around-the-clock, for the entire operating life of the sensor. The system includes a small implantable sensor based on fluorescence technology, a removable, water-resistant, smart transmitter worn on the upper arm over the sensor insertion site, and an easy-to-use mobile app. The transmitter calculates current glucose values and determines if they are expected to exceed pre-set low and high targets.
The data and alerts are simultaneously sent to the smartphone app, which provides real-time tracking, intuitive displays to help identify trending patterns, and predictive alerts before reaching both low or high glucose levels. Recent study results in both Type 1 and Type 2 diabetes patients showed that the Eversense CGM was safe and highly accurate over the previous, 90-day sensor life, with more than 93% of glucose values within an acceptable range of reference values. The study was published on January 30, 2018, in Diabetes Technology and Therapeutics.
“When we introduced the Eversense System last year, we were providing the longest-wear sensor with up to 90-day wear for people with diabetes. Now, with the new Eversense XL System’s even longer sensor duration, patients can extend a single sensor wear over three seasons, inserting a new sensor in the Fall which will continue through the Winter, to be replaced in Spring,” said Tim Goodnow, CEO and President of Senseonics. “As we continue to advance our product portfolio with extended long-term sensor capabilities, we are offering added convenience to support patients’ continuous glucose management.”
“We are all aware of the advantages of continuous glucose monitoring seen now in many studies, including improvements in glycemic control, quality of life, and reduction in hypoglycemia,” said Pratik Choudhary, MD, consultant in diabetes at King’s College London (United Kingdom). “The benefits have been linked with long-term usage, which for many requires changing sensors every week. Eversense now offers a unique option for people who want to use CGM long term, with a long-lasting sensor that has demonstrated accuracy.”